血清β<sub>2</sub>微球蛋白胱抑素C及血清α<sub>1</sub>微球蛋白水平与急性肾衰竭患者预后的相关性

doi:10.3969/j.issn.1006-6233.2023.08.010

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1411 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 分析血清β₂微球蛋白(β₂-MG)、胱抑素C(Cys C)及血清α₁微球蛋白(α₁-MG)水平与急性肾衰竭患者预后的相关性。方法: 回顾性分析2020年8月至2021年8月收治的105例急性肾衰竭患者的临床资料,根据患者入院时病情严重程度进行分期,将其分为Ⅰ期患者(n=41)、Ⅱ期患者(n=40)、Ⅲ期患者(n=24),比较不同时期患者入院时血清β₂-MG、Cys C、α₁-MG水平差异,再根据患者预后情况分为恢复组(肾功能恢复患者,n=67)和损伤组(肾功能永久性损伤患者,n=38),分析血清β₂-MG、Cys C、α₁-MG水平与急性肾衰竭患者预后的相关性,并探究血清β₂-MG、Cys C、α₁-MG水平对急性肾衰竭患者预后的评估效能。结果: Ⅲ期患者血清β₂-MG、Cys C、α₁-MG水平均高于Ⅱ期患者、Ⅰ期患者(P<0.05),Ⅱ期患者血清β₂-MG、Cys C水平均高于Ⅰ期患者(P<0.05)。恢复组患者β₂-MG、Cys C、α₁-MG水平均低于损伤组(P<0.05)。血清β₂-MG、Cys C、α₁-MG曲线AUC均明显高于参考线(AUC>0.5),其cut off值分别为3.59mg/L、3.21mg/L、33.36mg/L。结论: 血清β₂-MG、Cys C、α₁-MG水平与急性肾衰竭患者病情和预后相关。临床治疗急性肾衰竭需在血清β₂-MG水平>3.59mg/L、Cys C水平>3.21mg/L、α₁-MG水平>33.36mg/L前采取有效的治疗措施,以改善患者预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	徐海波
	徐良
	刘莉

关键词 ：血清β₂微球蛋白, 胱抑素C, 血清α₁微球蛋白, 急性肾衰竭, 预后, 相关性

Abstract：Objective: To analyze the correlation between levels of serum β₂ microglobulin (β₂-MG), cystatin C (Cys C) and serum α₁ microglobulin (α₁-MG) and prognosis in patients with acute renal failure. Methods: The clinical data of 105 patients with acute renal failure who were treated between August 2020 and August 2021 were retrospectively analyzed. According to the severity of disease at admission, the patients were divided into stage I patients (n=41), stage II patients (n=40), and stage III patients (n=24). The differences in levels of serum β₂-MG, Cys C and α₁-MG at admission were compared among patients at different stages. According to the prognosis, the patients were classified into recovery group (patients with renal function recovery, n=67) and injury group (patients with permanent renal function injury, n=38). The differences in serum β₂-MG, Cys C and α₁-MG at admission among patients with different prognosis status were compared, and the evaluated efficiency of serum β₂-MG, Cys C and α₁-MG on the prognosis in patients with acute renal failure was explored. Results: The levels of serum β₂-MG, Cys C and α₁-MG in stage III patients were higher than those in stage II patients and stage I patients (P<0.05). The level of serum β₂-MG and Cys C in stage II patients was higher than that in stage I patients (P<0.05). The levels of β₂-MG, Cys C and α₁-MG in recovery group were lower than those in injury group (P<0.05). Serum β₂-MG, Cys C and α₁-MG curves AUC were significantly higher than those of the reference lines (AUC>0.5), and their cut off values were 3.59mg/L, 3.21mg/L and 33.36mg/L respectively. Conclusion: Serum β₂-MG, Cys C and α₁-MG levels were correlated with the disease condition and the prognosis in patients with acute renal failure. It is necessary to take effective treatment measures before serum β₂-MG level >3.59mg/L, Cys C level >3.21mg/L and α₁-MG level >33.36mg/L in the clinical treatment of acute renal failure so as to improve the prognosis of patients.

Key words： Serum β₂ microglobulin Cystatin C Serum α₁ microglobulin Acute kidney failure Prognosis Correlation

基金资助:2022年度安徽省中医药传承创新科研项目,(编号:2022CCZD14)

引用本文:

徐海波, 徐良, 刘莉. 血清β₂微球蛋白胱抑素C及血清α₁微球蛋白水平与急性肾衰竭患者预后的相关性[J]. 河北医学, 2023, 29(8): 1283-1287.
XU Haibo, XU Liang, LIU Li. Correlation between Levels of Serum β₂ Microglobulin Cystatin C and Serum α₁ Microglobulin and Prognosis in Patients with Acute Renal Failure. HeBei Med, 2023, 29(8): 1283-1287.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2023.08.010 或 http://www.hbyxzzs.cn/CN/Y2023/V29/I8/1283